Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-03-19

Clinical Trial Update: Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate [Phase 2]

View source ↗

Summary

A Phase 2 crossover trial comparing sevelamer hydrochloride and sevelamer carbonate in chronic kidney disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Renagel (sevelamer)
  • Renvela (sevelamer carbonate)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Chronic Kidney Disease | Phase 2 | Status: COMPLETED